PDS Planning Inc Has $287,000 Holdings in Boston Scientific Co. (NYSE:BSX)

PDS Planning Inc boosted its position in shares of Boston Scientific Co. (NYSE:BSX) by 11.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,964 shares of the medical equipment provider’s stock after acquiring an additional 496 shares during the period. PDS Planning Inc’s holdings in Boston Scientific were worth $287,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Aspire Private Capital LLC lifted its position in Boston Scientific by 10.9% during the 4th quarter. Aspire Private Capital LLC now owns 7,885 shares of the medical equipment provider’s stock worth $456,000 after acquiring an additional 773 shares during the last quarter. California Public Employees Retirement System lifted its position in Boston Scientific by 3.0% during the 4th quarter. California Public Employees Retirement System now owns 3,798,511 shares of the medical equipment provider’s stock worth $219,592,000 after acquiring an additional 112,222 shares during the last quarter. Jennison Associates LLC lifted its position in Boston Scientific by 1.3% during the 4th quarter. Jennison Associates LLC now owns 1,227,833 shares of the medical equipment provider’s stock worth $70,981,000 after acquiring an additional 15,596 shares during the last quarter. Commerzbank Aktiengesellschaft FI bought a new position in shares of Boston Scientific during the 4th quarter worth about $366,000. Finally, Cetera Trust Company N.A bought a new position in shares of Boston Scientific during the 4th quarter worth about $43,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the transaction, the executive vice president now directly owns 56,508 shares of the company’s stock, valued at $3,779,820.12. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the transaction, the executive vice president now directly owns 56,508 shares of the company’s stock, valued at $3,779,820.12. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Edward J. Ludwig sold 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the completion of the transaction, the director now directly owns 41,374 shares in the company, valued at $2,690,551.22. The disclosure for this sale can be found here. Insiders have sold 50,979 shares of company stock valued at $3,418,529 over the last three months. 0.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on BSX shares. TD Cowen boosted their price objective on shares of Boston Scientific from $65.00 to $77.00 and gave the stock an “outperform” rating in a report on Thursday, March 7th. Royal Bank of Canada boosted their price objective on shares of Boston Scientific from $70.00 to $78.00 and gave the stock an “outperform” rating in a report on Monday, April 15th. Citigroup boosted their price objective on shares of Boston Scientific from $71.00 to $79.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. JPMorgan Chase & Co. boosted their price objective on shares of Boston Scientific from $60.00 to $72.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Finally, StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 16th. Two investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $68.50.

Boston Scientific Price Performance

BSX opened at $68.99 on Wednesday. Boston Scientific Co. has a one year low of $48.35 and a one year high of $69.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82. The company’s 50 day simple moving average is $67.39 and its 200-day simple moving average is $60.19. The stock has a market capitalization of $101.22 billion, a P/E ratio of 64.48, a price-to-earnings-growth ratio of 2.38 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, beating the consensus estimate of $0.51 by $0.04. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. The business had revenue of $3.73 billion for the quarter, compared to analysts’ expectations of $3.59 billion. During the same period in the prior year, the firm earned $0.45 earnings per share. Sell-side analysts anticipate that Boston Scientific Co. will post 2.25 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.